SCHEMBL162341

SCHEMBL162341

CON(C)C(=O)C(F)(F)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.46
RIPK1 Q13546 1/20 0.40
KCNN4 O15554 3/20 0.39
POLQ O75417 2/20 0.39
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
XBP1 P17861 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
HSD11B1 P28845 1/20 0.35
ATM Q13315 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500057 0.85 MEN1 (0.49) MLYCDRAB9AMEN1MAPTMAPK1
SCHEMBL3502057 0.82 RXFP1 (0.42) MLYCDNPC1RAB9ASMN1; SMN2
SCHEMBL6451094 0.81 PTGDR2 (0.43) MLYCDNPC1RAB9AMAPTCYP1A1
SCHEMBL18668218 0.80 RXRA (0.45) MLYCD
SCHEMBL2397913 0.77 GAA (0.48) MLYCDRIPK1SMN1; SMN2HSD11B1ALDH1A1
SCHEMBL20681716 0.75 MTNR1A (0.39) MLYCDRIPK1MAPTSMN1; SMN2ALDH1A1
SCHEMBL5762081 0.74 RAB9A (0.44) KCNN4NPC1RAB9AMEN1MAPT
SCHEMBL25006865 0.73 RIPK1 (0.41) MLYCDRIPK1RAB9AMEN1MAPT
SCHEMBL22670274 0.73 TSHR (0.46) MLYCDMAPK1SMN1; SMN2HSD11B1ALDH1A1
SCHEMBL29433296 0.73 TSHR (0.46) MLYCDMAPK1SMN1; SMN2HSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2663553-B1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS AMBIT BIOSCIENCES CORP (US) 2015-08-26 EP disclosed
EP-2663553-A2 QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-11-20 EP disclosed
US-20130296363-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS AMBIT BIOSCIENCES CORPORATION (US) 2013-11-07 US disclosed
WO-2012030944-A2 QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed
US-4616026-A Antifungal 2-aryl-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)2-propanols PFIZER INC. (US) 1986-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296363-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS JAK3, JAK2, JAK1 MLYCD 1921/4885RIPK1 83/4885KCNN4 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.